Stock ETNI ENTEST GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Entest Group, Inc.

Equities

ETNI

US29383T3005

Market Closed - OTC Markets
Other stock markets
 16:29:23 30/05/2024 BST 		5-day change 1st Jan Change
0.0001 USD -.--% Intraday chart for Entest Group, Inc. -.--% -.--%
2020 Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019 CI
2019 Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019
CI
ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
AQ
Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019
CI
ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019
CI
Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018
CI
Entest Group, Inc. Announces Management Changes
CI
Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.
CI
Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.
CI
Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.
PR
ENTB will Change its Name to ETNI
CI
Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board
PR
Entest BioMedical : Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities
PR
Entest Group, Inc. Auditor Raises 'Going Concern' Doubt
CI
Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D
CI
Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB
CI
Christine Ichim Joins Entest BioMedical Inc. as Director of Research
CI
Entest Biomedical Mulls Acquisitions
CI
Entest Biomedical, Inc. Announces the Research Study Conducted on ImenVax(TM)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ETNI Stock
  4. News Entest Group, Inc.